Navigation Links
AMT Provides Business Update for the First Quarter 2010
Date:5/19/2010

AMSTERDAM, May 19, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the first quarter of 2010.

    Q1 2010 Highlights

    - EMA starts formal review of Glybera(R) dossier
    - Dossier validated by EMA on January 20, 2010
    - Day 120 questions from EMA expected second half of May 2010
    - Innovation Credit received from Dutch Government for Duchenne Muscular
      Dystrophy
    - Up to EUR 4 million funding, repayable only on successful
      commercialization
    - Supports 35% of development costs through to 2013
    - Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
    - First patient dosed

Business Update

AMT's cash position* on March 31, 2010 amounted to EUR17.7 million compared to EUR22.6 million on December 31, 2009. The cash outflow in the first quarter of 2010, amounting to EUR4.9 million mainly represented operational cash flow. AMT employed 85 persons as of March 31, 2010. Total expenses in the first quarter of 2010 were EUR5.1 million compared to EUR4.9 million in the same period last year.

* The Company's cash position is composed of cash and cash equivalents.

Material events after March 31, 2010

On May 6, 2010'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. CardioDynamics Provides 2007 Shareholder Meeting Update
2. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
3. NxStage Medical Provides Update on Medisystems Acquisition
4. VaxGen Files 2006 Financial Statements and Provides Cash Update
5. Signalife Provides Corporate Update
6. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
7. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
8. SGX Provides Update on BCR-ABL Collaboration
9. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... , Ph.D., the Company,s Vice President, Biology and ... Relations & Corporate Communications, will present an overview of ... 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) during ...
(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... Kill Human Embryos for Research, LANSING, Mich., ... Executive Officer Sister Monica Kostielney,R.S.M., made the following ... committee "Stem Cell Research BQC":, "In order ... stage, any,proposal, legislative or ballot related, that seeks ...
... AMDL, Inc. (Amex:,ADL), headquartered in Tustin, ... China, through its wholly owned subsidiary Jade,Pharmaceutical ... that,engages in the development, manufacture and marketing ... today that JPI has,signed an agreement with ...
... Compendia Bioscience, Inc.,today announced the receipt of a ... Cancer Institute to support the project entitled "Development,of ... and,Development". (Logo: http://www.newscom.com/cgi-bin/prnh/20070213/NYTU093LOGO ) ... as the principal,investigator for this project, will assume ...
Cached Biology Technology:AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually 2Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes 2
(Date:5/24/2013)... medication against Alzheimer,s disease, scientists have focused among other ... (A-beta). After all, it is the accumulation of A-beta that ... Starting point for the formation of A-beta is APP. Alessia ... unravel the function of APPL the fruit-fly version of ... , Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... Northwest National Laboratory honored more than 165 staff ... property at PNNL,s annual Intellectual Property Commercialization Recognition ... of Energy national laboratory named materials scientist Jun ... developing battery materials that can store large amounts ... and reduce the time it takes to charge ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... nuclear weapons remains a goal for governments around the ... 21st century, as recognised at the 2010 nuclear security ... efforts to prevent the proliferation of nuclear weapons, but ... the important role science in this field. A new ...
... A panel of scientists speaking today at the annual meeting ... unveiled new research and models demonstrating how climate change could ... coastal and Great Lakes ecosystems, with some studies projecting impacts ... the wettest year on record and third warmest for sea ...
... Researchers from the Georgia Institute of Technology have ... of people worldwide from dying of pneumonia each year. ... is a solution to the problem of diagnosing pneumonia, ... for Disease Control and Prevention (CDC). Pneumonia, an ...
Cached Biology News:Enhancing nuclear security: Training and international collaboration 2Climate projections show human health impacts possible within 30 years 2Climate projections show human health impacts possible within 30 years 3Climate projections show human health impacts possible within 30 years 4A better way to diagnose pneumonia 2A better way to diagnose pneumonia 3
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Biology Products: